Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong growth in MRD products, promising new indications, and strategic partnerships. Despite some challenges in the translational sector and policy headwinds, the company shows resilience with significant revenue growth and optimistic guidance. The Tempus partnership and expansion plans further support a positive outlook. While there are some uncertainties, the overall sentiment leans towards positive due to high growth rates, strategic positioning, and potential reimbursement achievements.
Key Financial Performance
Total Revenue $17.2 million in Q2 2025, a 24% decrease year-over-year from $22.6 million in Q2 2024. The decrease was primarily driven by a $5.6 million decline from Natera and a $1.3 million decline from Moderna due to expected volume reductions and project delays.
Biopharma Revenue $11.1 million in Q2 2025, a 16% decrease year-over-year from $13.2 million in Q2 2024. The decline was mainly due to reduced revenue from Moderna and delays in customer projects.
Clinical Revenue $0.5 million in Q2 2025, compared to $0.1 million in Q2 2024, showing significant growth driven by increased adoption of NeXT Dx and NeXT Personal molecular tests.
Gross Margin 27.6% in Q2 2025, down from 35.6% in Q2 2024. The 8% decrease was primarily due to lower revenue and unreimbursed clinical test costs, which impacted gross margin by approximately 12%. Excluding these costs, gross margin would have been approximately 40%.
Operating Expenses $26.6 million in Q2 2025, up from $24.9 million in Q2 2024. The increase was mainly attributed to higher selling expenses related to clinical test volume growth.
R&D Expense $12.4 million in Q2 2025, down from $13 million in Q2 2024, reflecting a slight reduction in research and development spending.
SG&A Expense $14.2 million in Q2 2025, up from $11.9 million in Q2 2024, driven by increased selling expenses.
Net Loss $20.1 million in Q2 2025, compared to $12.8 million in Q2 2024. The prior year's net loss included a $3 million noncash gain related to warrants issued to Tempus. Excluding this gain, the prior year net loss would have been $15.8 million, indicating a year-over-year increase in net loss.
Cash and Short-term Investments $173.2 million as of the end of Q2 2025, with no significant debt other than small equipment loans.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NeXT Personal test: Monitors therapy and detects residual cancer with ultrasensitivity, capable of finding just one fragment of tumor DNA in a million. Clinical adoption is accelerating with test volume growing 59% sequentially, delivering nearly 3,500 clinical results in Q2. Expanded partnership with Tempus to include colorectal cancer.
MRD market: Personalis is targeting the minimal residual disease market, which is poised to exceed $20 billion annually. The company is positioning itself to capture a significant share of this market.
Revenue performance: Q2 revenue was $17.2 million, a 24% decrease year-over-year. Full-year revenue guidance revised to $70-$80 million due to industry-wide headwinds in biopharma R&D spending and project delays.
Clinical business growth: Clinical business is exceeding internal plans with 30%-40% quarter-over-quarter growth projected. Partnership with Tempus is a key driver.
Biopharma revenue: Biopharma revenue was $11.1 million in Q2, reflecting a 16% decrease year-over-year due to project delays and declines from major customers like Moderna.
Reimbursement goals: Personalis is on track to secure Medicare coverage for 2 indications by the end of the year, which is expected to unlock significant revenue streams.
Expansion of sales force: The company plans to increase its sales force to 12-15 field professionals by year-end to support growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Biopharma R&D Spending Headwinds: The company is facing industry-wide headwinds in biopharma R&D spending, which has led to delays in customer translational research projects and revenue shifts.
Revenue Decline: Total company revenue decreased by 24% year-over-year, driven by volume declines from key customers like Natera and Moderna, and delays in biopharma projects.
Gross Margin Pressure: Gross margin decreased to 27.6% from 35.6% year-over-year, primarily due to lower revenue and unreimbursed clinical test costs.
Customer Project Delays: Delays in customer projects have impacted biopharma revenue, which would have otherwise increased year-over-year.
Unreimbursed Clinical Test Costs: The company incurred significant unreimbursed clinical test costs, impacting gross margins by approximately 12%.
Regulatory and Reimbursement Uncertainty: The timing and outcome of Medicare reimbursement for key indications remain uncertain, which could affect future revenue streams.
Increased Operating Expenses: Operating expenses increased year-over-year, driven by higher selling expenses related to clinical test volume growth.
Cash Usage: The company expects cash usage for 2025 to increase by $30 million compared to 2024, primarily due to investments in clinical test volumes, new studies, and sales team expansion.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has updated its full-year revenue guidance to a range of $70 million to $80 million, down from the previous range of $80 million to $90 million. This reflects variability in biopharma project timing and market conditions.
Biopharma Revenue: Biopharma revenue is projected to rebound to $11 million to $13 million in Q3 2025, with higher expectations for Q4, which is typically the strongest quarter. NeXT Personal revenue from biopharma is expected to grow 300% to 400% year-over-year, with meaningful contributions in Q4.
Clinical Business Growth: The clinical business is projected to grow 30% to 40% quarter-over-quarter, driven by the adoption of NeXT Personal and partnerships like Tempus. The company expects to exit the year with 12 to 15 field professionals to support this growth.
Medicare Reimbursement: The company is on track to achieve Medicare reimbursement for two indications by the end of 2025, which is expected to unlock significant revenue streams and serve as a major inflection point.
Gross Margin Outlook: Gross margins are expected to expand beyond 50% once reimbursement coverage is obtained for multiple indications and scale is achieved. However, for 2025, gross margins are expected to be in the range of 22% to 24%, down from 32% in 2024, due to investments in clinical test volumes ahead of reimbursement.
Cash Usage: Cash usage for 2025 is expected to be approximately $75 million, up from $45 million in 2024, primarily due to investments in clinical test volumes, clinical evidence expansion, and sales team additions.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What was the rationale for lowering the top end of the guidance from 3%-10% to 3%-6% for Medicare?
A:The range was narrowed because the company is now in August and has better visibility. The prior guide had a wide range due to uncertainty about reimbursement timing. Now, they estimate $3 million to $6 million, assuming reimbursement for one indication in Q3 and another in Q4. They are targeting two cancer types for the full year.
Q:How is the early use of the ultrasensitive test progressing, and what are the key areas of focus?
A:The test is being used in breast cancer, lung cancer, therapy, and IO therapy monitoring. Doctors have used it to detect recurrence months ahead, guide post-neoadjuvant decisions, and monitor therapy. About 40% of positive results are in the ultrasensitive range, which has driven high retention and adoption. CRC has been added to the call cycle, and feedback has been positive.
Q:What is the company's cash position and outlook for cash flow?
A:The company has $173 million in cash and burned $13 million in the quarter. They believe they have enough cash to reach reimbursement and cash flow breakeven. There are no plans to raise additional funds, and they are investing in studies and growth.
Q:Is the $10 million reduction in biopharma revenue a pushout or a cancellation?
A:The reduction is a pushout rather than a cancellation. Some projects have been delayed to Q3 and Q4, and there is general softness in the translational sector due to biopharma layoffs and tighter budgets. However, the MRD product is performing well with 300%-400% growth and two customers generating over $5 million each.
Q:What is driving growth in NeXT Personal tests, and how is it linked to NeXT Dx CGP tests?
A:Growth is driven by an increasing number of physicians (over 600) and more samples per physician. The Tempus partnership has been instrumental. NeXT Dx CGP tests are often appended to NeXT Personal tests, driving additional revenue.
Q:What improvements have been made in turnaround time for tests?
A:Turnaround times have improved significantly due to focused R&D efforts over the past 18 months. The company is now competitive with other vendors in the market, and operational execution has been strong, as evidenced by high retention and growth.
Q:What is the cadence of repeat testing by physicians?
A:It is still early to determine definitively, but recurrence monitoring has a lower cadence than IO therapy monitoring. The company expects more insights as numbers grow.
Q:How does the company plan to manage its relationship with Tempus as it expands its sales team?
A:The Tempus infrastructure is preferred for logistics and EMR integration. The company's sales team focuses on supporting Tempus relationships, working with KOLs, and covering market gaps where Tempus is not present.
Q:What is the impact of policy headwinds on biopharma customers?
A:Policy headwinds have caused delays in translational research projects, pushing some revenue into future quarters. However, MRD offerings continue to grow, and the company expects to fulfill commitments from two $5 million customers this year.
Q:How does the company differentiate NeXT Personal from competitors like Saga?
A:NeXT Personal uses a whole-genome approach with 1,800 variants, which is more cost-intensive and potentially more comprehensive than Saga's 16-variant exome-based approach. The company is investing in evidence development and prospective clinical trials to strengthen its position.
Q:What is the company's strategy for balancing MRD investments with margin pressures?
A:The company is prioritizing volume growth to maximize revenue upon reimbursement. They are managing cash burn prudently while achieving high growth rates (50% sequentially) and targeting 30%-40% growth going forward.
Q:What were the key takeaways from ASCO, and how will they influence future plans?
A:The company presented data showing that their test is highly predictive of relapse in neoadjuvant breast cancer, independent of PAT CR. This supports plans to expand MolDx coverage to include neoadjuvant breast cancer once studies are published.
Q:What is the company's outlook on pricing and reimbursement for MRD tests?
A:Pricing discussions will occur after coverage is obtained. The company expects reimbursement to be at least on par with current market rates for 16-variant exome-based tests, with potential upside due to the whole-genome approach.
Q:Has the lack of reimbursement led to erosion in interest from doctors?
A:No, the company has not seen erosion in interest. They continue to expand the number of doctors using the test and are focusing on deepening relationships by demonstrating the value of the ultrasensitive range.
Q:How will reimbursement impact revenue recognition?
A:Revenue recognition will depend on the timing of coverage decisions and the number of samples processed. The company has guided $3 million to $6 million in revenue for Q4, assuming favorable coverage.
Q:What is the status of colorectal cancer data and plans for reimbursement?
A:Preliminary data from the Victory study is promising but not yet sufficient for reimbursement. The investigator will decide when to lock the study, after which it will be published and submitted for reimbursement.
Q:What is causing the slowdown in pharma test and services revenue?
A:The slowdown is due to delays in translational research projects caused by biopharma layoffs and tighter budgets. However, MRD offerings are growing rapidly, and the company expects translational research to recover as market conditions improve.
Q:How will the Tempus arrangement adapt to reimbursement for specific cancer types?
A:Most samples already align with core indications like lung and breast cancer. While the company can encourage focus on reimbursed indications, physicians prefer consistent access to the technology for all patients.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact timing of reimbursement decisions, the precise pricing for MRD tests, and the cadence of repeat testing by physicians. They also did not clarify the full impact of policy headwinds on long-term biopharma revenue or provide a detailed timeline for colorectal cancer data publication and reimbursement submission.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AstraZeneca test
BTIG LLC
Bais BTIG
CEO Director
CFO COO
COO Hall
Capital Markets
Co LLC
Conference Instructions
Corner Westwicke
Cowen Research
DNA cancer
Director Chen
Division Corner
Division Flaten
LLC Research
MRD adoption
Medicare coverage
Research Division
adoption Personal
base physician
biopharma project
coverage indication
dossier
industry
light
momentum
month imaging
partner technology
pillar
plan
tool
track
ultrasensitivity
win MRD
PSNL Transcript
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call summary reflects strong quarterly growth, with a 26% increase in tests and a clear focus on expanding clinical volumes. The company's confidence in their ultrasensitive testing approach and strategic partnerships, along with improving gross margins and aggressive reimbursement strategies, indicate positive market sentiment. Despite some unclear responses in the Q&A, the overall outlook remains optimistic, especially with upcoming presentations at ASCO and a growing biopharma backlog. These factors suggest a positive stock price movement over the next two weeks.
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
Unknown2-26
Despite some operational improvements, the earnings call highlighted significant challenges, including a 15% revenue decline and reduced gross margins. Although net loss and cash flow improved, the revised revenue guidance and uncertainties around reimbursement decisions and collaborations present risks. These factors, combined with the absence of positive new developments or partnerships, suggest a negative sentiment overall.
Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call highlights several challenges: reduced revenue guidance, logistical delays, and increased expenses. Despite positive developments like new customer onboarding and potential Medicare reimbursement, the lowered guidance and uncertainties in timelines overshadow the positives. The Q&A session reveals cautious management responses and possible revenue delays into Q1. These factors, combined with increased cash usage and reduced gross margin projections, suggest a negative market reaction in the short term, likely leading to a stock price decline of -2% to -8%.
Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call summary and Q&A indicate strong growth in MRD products, promising new indications, and strategic partnerships. Despite some challenges in the translational sector and policy headwinds, the company shows resilience with significant revenue growth and optimistic guidance. The Tempus partnership and expansion plans further support a positive outlook. While there are some uncertainties, the overall sentiment leans towards positive due to high growth rates, strategic positioning, and potential reimbursement achievements.
PSNL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
